We are live on ! Find out more
OMIC

Singular Genomics Systems, Inc. Common Stock

Delisted

OMIC was delisted on the 20th of February, 2025.

24 hedge funds and large institutions have $6M invested in Singular Genomics Systems, Inc. Common Stock in 2024 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 11 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

43% less funds holding

Funds holding: 4224 (-18)

45% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 11

54% less capital invested

Capital invested by funds: $13.1M → $6M (-$7.05M)

90% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 20

Holders
24
Holders Change
-18
Holders Change %
-42.86%
% of All Funds
0.35%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
2
Increased
6
Reduced
11
Closed
20
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
DM
1
Deerfield Management
New York
$1.4M
AVM
2
Arch Venture Management
Illinois
$1.07M -$12 -1 -0%
QM
3
QVIDTVM Management
Texas
$706K +$12 +1 +0%
PA
4
Perceptive Advisors
New York
$599K
Fidelity Investments
5
Fidelity Investments
Massachusetts
$597K -$23 -2 -0%
Vanguard Group
6
Vanguard Group
Pennsylvania
$527K -$23 -2 -0%
CC
7
Casdin Capital
New York
$373K -$12 -1 -0%
BlackRock
8
BlackRock
New York
$173K -$49K -4,187 -17%
O
9
OrbiMed
New York
$152K
HighTower Advisors
10
HighTower Advisors
Illinois
$150K -$47 -4 -0%
Geode Capital Management
11
Geode Capital Management
Massachusetts
$142K +$16.5K +1,414 +9%
TM
12
Tikvah Management
North Carolina
$89.2K -$12 -1 -0%
TRCT
13
Tower Research Capital (TRC)
New York
$4.46K +$3.85K +329 +165%
Barclays
14
Barclays
United Kingdom
$3.46K
Bank of America
15
Bank of America
North Carolina
$3.1K +$129 +11 +3%
Morgan Stanley
16
Morgan Stanley
New York
$3.07K +$854 +73 +25%
Royal Bank of Canada
17
Royal Bank of Canada
Ontario, Canada
$1K +$234 +20 +30%
RhumbLine Advisers
18
RhumbLine Advisers
Massachusetts
$464
BNP Paribas Financial Markets
19
BNP Paribas Financial Markets
France
$304 +$421 +36 New
Qube Research & Technologies (QRT)
20
Qube Research & Technologies (QRT)
United Kingdom
$186 -$12 -1 -4%
JP Morgan Chase
21
JP Morgan Chase
New York
$169 -$14.9K -1,274 -98%
HI
22
Harbour Investments
Wisconsin
$42 -$12 -1 -17%
UBS Group
23
UBS Group
Switzerland
-$1.14M -73,646 Closed
Verition Fund Management
24
Verition Fund Management
Connecticut
-$257K -16,667 Closed
TM
25
Triatomic Management
California
-$100K -6,491 Closed

OMIC Hedge Fund Activity: Q2 2024 in Review

24 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Singular Genomics Systems, Inc. Common Stock (OMIC) for Q2 2024, worth a combined $6M — down 54% from $13.1M a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of OMIC and 2 opened new positions — a net loss of 18 holders — while 11 trimmed existing stakes and 6 added.

The largest buyer was Geode Capital Management, adding an estimated $16.5K. The largest seller was UBS Group, exiting entirely with an estimated $1.14M sold.

  • 24 institutional investors held Singular Genomics Systems, Inc. Common Stock (OMIC) as of Q2 2024, down from 42 in Q1 2024.
  • Funds reported $6M of Singular Genomics Systems, Inc. Common Stock stock for Q2 2024, down 54% quarter-over-quarter.
  • 2 funds opened new Singular Genomics Systems, Inc. Common Stock positions in Q2 2024 and 20 closed out, a net change of -18 holders.
  • The largest Singular Genomics Systems, Inc. Common Stock buyer in Q2 2024 was Geode Capital Management, an estimated $16.5K added.
  • The largest Singular Genomics Systems, Inc. Common Stock seller in Q2 2024 was UBS Group, an estimated $1.14M sold.

Based on aggregated 13F filings for Q2 2024.